Nasdaq · Common stock

ADARx Pharmaceuticals (ADRX)

$17.81 +$0.18 (+1.02%)

Day’s range: $17.50–$19.07
Volume: 99,579

Monday’s close

ADRX price history

ADRX closed at $17.81 on Oct. 26, 2026. Over the past year, its daily close ranged from $17.13 on Oct. 21, 2026 to $20.64 on Sept. 29, 2026.

Source: third-party providers. Daily closing prices, adjusted for stock splits; dividends not included. The price scale runs from $17 to $21, not from zero. As of the close on Oct. 26, 2026

Data table: ADRX daily closes, the past year

ADRX daily closing prices, Sept. 25, 2026 to Oct. 26, 2026, newest first
Date	Close
Oct. 26, 2026	$17.81
Oct. 23, 2026	$17.63
Oct. 22, 2026	$17.68
Oct. 21, 2026	$17.13
Oct. 20, 2026	$17.68
Oct. 19, 2026	$17.63
Oct. 16, 2026	$17.65
Oct. 15, 2026	$17.70
Oct. 14, 2026	$17.83
Oct. 13, 2026	$17.70
Oct. 12, 2026	$17.97
Oct. 9, 2026	$17.78
Oct. 8, 2026	$17.68
Oct. 7, 2026	$17.33
Oct. 6, 2026	$18.58
Oct. 5, 2026	$19.05
Oct. 2, 2026	$18.25
Oct. 1, 2026	$19.54
Sept. 30, 2026	$19.94
Sept. 29, 2026	$20.64
Sept. 28, 2026	$20.09
Sept. 25, 2026	$19.35

Key figures

Average daily volume: 763,360Past 3 months
Market value: $1.90B
Dividend yield: —

Price change

1 month: −7.96%

Monday’s close

What Wall Street says about ADRX

In the past 90 days, Wall Street firms published 4 rating or price-target actions on ADRX: 4 new ratings.

Rating and price-target actions on ADRX, past 90 days
	Action	Rating
JP Morgan	Initiates coverage	Overweight	$38	Oct. 20
Morgan Stanley	Initiates coverage	Overweight	$32	Oct. 20
TD Cowen	Initiates coverage	Buy	—	Oct. 20
UBS	Initiates coverage	Buy	$35	Oct. 20

Ratings and price targets are the firms’ own opinions, reported as published.

Not investment advice.

About ADARx Pharmaceuticals, Inc. Common Stock

Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

Listed: Sept. 25, 2026

adarx.com, the company’s website

In WallStreetDigest editions

No WallStreetDigest article about ADRX is on the site yet.